57543-60-9

Usage

Uses

Used in Pharmaceutical Industry:
7-Methoxy-2H-chromene-3-carboxylic acid is used as a pharmaceutical candidate for its potential therapeutic properties, such as its anti-inflammatory and antioxidant activities. Its cytotoxic effects on cancer cells make it a promising agent for the development of new drug compounds for various medical applications.
Used in Anticancer Applications:
7-Methoxy-2H-chromene-3-carboxylic acid is used as an anticancer agent, exhibiting cytotoxic effects on cancer cells. Its potential to target and inhibit the growth of cancer cells makes it a valuable compound in the development of new cancer treatments.
Used in Drug Development:
7-Methoxy-2H-chromene-3-carboxylic acid is used in the development of new drug compounds for various medical applications. Its unique structure and pharmacological properties make it a target for further research and potential drug development, offering the possibility of discovering novel therapeutic agents with improved efficacy and safety profiles.

Upstream product

• 83823-25-0 7-Methoxy-2H-chromene-3-carboxylic acid amide 
• 673-22-3 2-Hydroxy-4-methoxybenzaldehyde 
• 95-01-2 2,4-Dihydroxybenzaldehyde 
• 108-46-3 recorcinol 
• 151510-36-0 7-Methoxy-2H-chromene-3-carboxylic acid tert-butyl ester 
• 854673-90-8 3-(2-formyl-5-methoxy-phenoxy)-propionic acid 
• 57543-70-1 7-methoxybenzo-2H-pyran-3-carbonitrile 

Downstream Products

• 3187-51-7 7-methoxychromane-3-carboxylic acid 
• 86236-08-0 carbomethoxy-3 methoxy-7 2H chromene 
• 76322-24-2 7-methoxychroman-3-one 
• 6054-09-7 pyrano[3,2-g][1]benzopyran-2-one 
• 86116-44-1 2-Oxo-2H,8H-pyrano[3,2-g]chromene-3-carboxylic acid ethyl ester 

Relevant academic research and scientific papers

Rational design and synthesis of novel 2-(substituted-2H-chromen-3-yl)-5-aryl-1H-imidazole derivatives as an anti-angiogenesis and anti-cancer agent

Based on earlier proven pharmacophore analogues of cancer a novel 2-(substituted-2H-chromen-3-yl)-5-aryl-1H-imidazoles (13-16) were rationally designed and synthesized by the reaction of chromene-3-carboxylic acids (10a-d) with substituted acyl bromides in the presence of TEA followed by refluxing with NH4OAc in toluene. Compounds 13-16 were screened in vitro for the inhibition of KRAS/Wnt and their anti-angiogenesis properties. Compound 16f has been identified as a potent anti-angiogenesis molecule, which can be considered as a new lead structure. The molecular docking analysis displayed the higher binding affinity of 16f with KRAS, Wnt and VEGF.

ANTAGONISTS OF THE TRPV1 RECEPTOR AND USES THEREOF

The present application is directed to compounds that are TRPV1 antagonists and have formula (I) wherein variables Ar1, L1, R1, R2, R3, R4, R5, Y1, Y2, and Y3, are as defined in the description, which are useful for treating disorders caused by or exacerbated by vanilloid receptor activity.

ARYLSULFONYLMETHYL OR ARYLSULFONAMIDE SUBSTITUTED AROMATIC COMPOUNDS SUITABLE FOR TREATING DISORDERS THAT RESPOND TO MADULATION OF THE DOPAMINE D3 RECEPTOR

The present invention relates to aromatic compounds of the formula (I), wherein Ar is phenyl or an aromatic 5- or 6-membered C-bound heteroaromatic radical, wherein Ar may carry 1 radical Ra and wherein Ar may also carry 1 or 2 radicals Rb; X is N or CH; Y is O, S, -CH=N-, -CH=CH- or -N=CH-; A is CH2i O or S; E is CR6R7 or NR 3; R1 is C1-C4-alkyl, C3-C4-cycloalkyl, C3-C4-cycloalkylmethyl, C3-C4-alkenyl, fluorinated C1-C4--alkyl, fluorinated C3-C4-cycloalkyl, fluorinated C3-C4-cycloalkylmethyl, fluorinated C3-C4--alkenyl, formyl or C,-C3-alkylcarbonyl; R1a is H, C2-C4-alkyl, C3-C4-cycloalkyl, C3-C4-alkenyl, fluorinated C1-C4-alkyl, fluorinated C3-C4 -cycloalkyl, or R1a and R2 together are (CH2)n with n being 2 or 3, or R1a and R2a together are (CH2)n with n being 2 or 3; R2 and R2a are independently of each other H, CH3, CH2F, CHF2 or CF3; R3 is H or C1-C4-alkyl; R6, R7 independently of each other are selected from H, C1-C2-alkyl and fluorinated C1-C2-alkyl; and the physiologically tolerated acid addition salts thereof. The invention also relates to the use of a compound of the formula I or a pharmaceutically acceptable salt thereof for preparing a pharmaceutical composition for the treatment of a medical disorder susceptible to treatment with a dopamine D3 receptor ligand.

Substituted chromenes as potent, orally active 5-lipoxygenase inhibitors

A series of chromene derivatives was synthesized and evaluated for their in vitro and ex vivo 5-lipoxygenase (5-LO) inhibitory activity. These compounds were prepared by condensation of appropriate salicyl aldehydes with α,β-unsaturated carbonyl compounds

Chromene and Chroman 3-Carboxamides and Some Related Compounds as a New Class of Centrally Acting Agents

A number of chromene-3-carboxamides (7), 3-Aminochromans (11) and 3-aminomethylchromans (9) have been synthesized.Chromene-3-carboxamides have been found to exhibit strong central muscle relaxant activity compared to mephesin.